Stockscreener 앱 받기
44.47
0.32%
0.14
시간 외 거래:
44.67
0.20
+0.45%
전일 마감가:
$44.33
열려 있는:
$44.35
하루 거래량:
2.33M
Relative Volume:
0.84
시가총액:
$5.90B
수익:
-
순이익/손실:
$-237.54M
주가수익비율:
-17.76
EPS:
-2.5033
순현금흐름:
$-145.05M
1주 성능:
-5.46%
1개월 성능:
+88.83%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$42.50
$45.38
1주일 범위
$42.42
$47.20
52주 변동 폭
$14.62
$49.20
Definium Therapeutics Inc Stock (DFTX) Company Profile
명칭
Definium Therapeutics Inc
전화
212-220-6633
주소
ONE WORLD TRADE CENTER, NEW YORK
Compare DFTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DFTX
Definium Therapeutics Inc
|
44.47 | 5.88B | 0 | -237.54M | -145.05M | -2.5033 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Definium Therapeutics Inc Stock (DFTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-17 | 개시 | Stifel | Buy |
| 2026-04-10 | 개시 | Piper Sandler | Overweight |
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2026-01-30 | 개시 | Jefferies | Buy |
| 2025-10-13 | 개시 | Needham | Buy |
| 2025-08-04 | 재개 | Oppenheimer | Outperform |
| 2025-01-28 | 개시 | Evercore ISI | Outperform |
| 2024-12-20 | 개시 | Chardan Capital Markets | Buy |
| 2024-10-14 | 재개 | Leerink Partners | Outperform |
| 2024-07-24 | 개시 | ROTH MKM | Buy |
| 2024-05-29 | 개시 | Robert W. Baird | Outperform |
| 2024-04-15 | 개시 | Leerink Partners | Outperform |
| 2023-12-05 | 개시 | Canaccord Genuity | Buy |
| 2022-12-09 | 재개 | ROTH Capital | Buy |
| 2022-11-16 | 개시 | RBC Capital Mkts | Outperform |
| 2022-08-26 | 개시 | Oppenheimer | Outperform |
| 2022-08-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-05-04 | 개시 | ROTH Capital | Buy |
| 2021-06-28 | 개시 | Maxim Group | Buy |
모두보기
Definium Therapeutics Inc 주식(DFTX)의 최신 뉴스
Definium Therapeutics Announces New Employee Inducement Grants - Business Wire
Earnings call transcript: Definium’s Q1 2026 EPS miss overshadows strategic advances - Investing.com
Definium earnings on deck as pivotal psychedelic trial data looms By Investing.com - Investing.com India
DFTXDefinium Therapeutics Inc Volatility & Greeks - Finviz
Enterprise value to EBITDA forward of Definium Therapeutics, Inc. – NASDAQ:DFTX - TradingView
LSD therapy biotech Definium fends off trade-secret lawsuit - Reuters
DFTX Stock Clocks Best Day In Over Two Years On 'Best-Case' Clinical Results For Oral Lysergide In Depression - Stocktwits
Definium Therapeutics (DFTX) Institutional Ownership 2026 - MarketBeat
Definium Therapeutics Completes $805 Million Upsized Public Offering - Global Legal Chronicle
DFTX Maintained by Canaccord Genuity -- Price Target Lowered to $58 - GuruFocus
Hogan Lovells advises Definium Therapeutics, Inc. in Upsized Public Offering - Legal Desire Media and Insights
Is Definium Therapeutics, Inc. (DFTX) Stock Poised for Further Gains After Positive Emerge Trial Update? - Insider Monkey
Top 3 Health Care Stocks That May Keep You Up At Night In June - Benzinga
Canaccord cuts Definium Therapeutics stock price target on share count - Investing.com
CCORF Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Cuts Target Price to $58 - Moomoo
Analysts Are Bullish on Top Healthcare Stocks: Crinetics Pharmaceuticals (CRNX), Definium Therapeutics (DFTX) - The Globe and Mail
Definium Therapeutics stock hits 52-week high at 47.01 USD By Investing.com - Investing.com Nigeria
Definium Therapeutics stock hits 52-week high at 47.01 USD - Investing.com
Definium Therapeutics, Inc.(NasdaqGS:DFTX) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Definium Therapeutics, Inc.(NasdaqGS: DFTX) dropped from Russell 3000E Index - marketscreener.com
Definium Therapeutics, Inc.(NasdaqGS:DFTX) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Definium Therapeutics, Inc.(NasdaqGS: DFTX) dropped from Russell Microcap Index - marketscreener.com
Definium Therapeutics, Inc.(NasdaqGS:DFTX) dropped from Russell 3000 Value Benchmark - marketscreener.com
Definium Therapeutics, Inc.(NasdaqGS:DFTX) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
10 Best Biotech Stocks to Buy According to Analysts - Insider Monkey
DFTX Vs CMPS: Which Stock Has More Upside From Trump’s New Psychedelic Therapy Push? - Stocktwits
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Definium Therapeutics, Inc.(NasdaqGS:DFTX) dropped from Russell 3000E Value Benchmark - marketscreener.com
Price to sales forward of Definium Therapeutics, Inc. – NASDAQ:DFTX - TradingView
Enterprise value to revenue forward of Definium Therapeutics, Inc. – NASDAQ:DFTX - TradingView
Enterprise value to EBIT forward of Definium Therapeutics, Inc. – HAM:MMQ0 - TradingView
Price to sales forward of Definium Therapeutics, Inc. – HAM:MMQ0 - TradingView
Price to earnings forward of Definium Therapeutics, Inc. – NASDAQ:DFTX - TradingView
Price to book forward of Definium Therapeutics, Inc. – HAM:MMQ0 - TradingView
Price to earnings forward of Definium Therapeutics, Inc. – HAM:MMQ0 - TradingView
LifeSci Capital Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $63 - Moomoo
ETFs Investing in Definium Therapeutics, Inc. Stocks - TradingView
Price to earnings ratio of Definium Therapeutics, Inc. – HAM:MMQ0 - TradingView
Definium Therapeutics Prices Offering of Nearly 20.6M Shares at $34.00 Each >DFTX - Moomoo
Definium Therapeutics (DFTX) CLO sells 13,008 shares to cover RSU taxes - Stock Titan
Definium Therapeutics (DFTX) CMO sells 10,035 shares to cover RSU taxes - Stock Titan
Definium raises $805 million after positive Phase III depression data - The Pharma Letter
Definium Therapeutics, Inc. Announces Closing - Moomoo
Definium Therapeutics (DFTX) CFO disposes 3,013 shares to cover RSU taxes - Stock Titan
Form 144 DEFINIUM THERAPEUTICS For: 25 June By Investing.com - Investing.com South Africa
Definium Therapeutics prices $700M upsized public offering at $34.00 a share - MSN
Top Definium Therapeutics (DFTX) Competitors 2026 - MarketBeat
Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares - BioSpace
Definium Therapeutics closes $805 million stock offering - Investing.com UK
Definium Therapeutics Company Profile & Introduction - Moomoo
Definium Therapeutics, Inc. Actuals & Estimates (NASDAQ:DFTX) - TradingView
Definium Therapeutics Inc (DFTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Definium Therapeutics Inc 주식 (DFTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Roberts Brandi | Chief Financial Officer |
Jun 25 '26 |
Sale |
45.03 |
3,013 |
135,675 |
209,487 |
| Barrow Robert | Chief Executive Officer |
Jun 25 '26 |
Sale |
45.03 |
29,208 |
1,315,236 |
1,098,246 |
| Karlin Daniel | Chief Medical Officer |
Jun 25 '26 |
Sale |
45.03 |
10,035 |
451,876 |
503,282 |
| Wiley Matthew T. | Chief Commercial Officer |
Jun 25 '26 |
Sale |
45.03 |
2,867 |
129,101 |
174,633 |
1.18%
2.48%
자본화:
|
볼륨(24시간):